280
Views
10
CrossRef citations to date
0
Altmetric
Letter

Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib

, &
Pages 332-333 | Received 18 Apr 2011, Accepted 15 Jul 2011, Published online: 19 Sep 2011

References

  • Druker BJ, Talpaz M, Resta DJ, . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
  • Druker BJ, Sawyers CL, Kantarjian H, . Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038–1042.
  • Ohnishi K, Sakai F, Kudoh S, . Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162–1164.
  • Seki N, Ito A, Watanabe K, . Irreversible imatinib-induced pneumonitis following long-term imatinib administration. Intern Med 2007;46:1941–1942.
  • Bergeron A, Réa D, Levy V, . Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007;176:814–818.
  • Swords R, Mahalingam D, Padmanabhan S, . Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther 2009;3:89–101.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.